Work

Phase II trial of irinotecan/temozolomide/dinutuximab/granulocyte macrophage colony stimulating factor (I/T/DIN/GMCSF) in children with relapsed/refractory neuroblastoma (NBL): A report from the Children's Oncology Group (COG).

Year: 2018

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2018.36.15_suppl.10508

Authors: Rajen Mody, Arlene Naranjo, Alice L. Yu, Emily Hibbitts, Wendy B. London, Barry L. Shulkin, Marguerite T Parisi, Sabah-E-Noor Servaes, Mitchell B Dicciani, Paul M. Sondel, Julia Glade-Bender, Howard Katzenstein, John Maris, Julie R. Park, Rochelle Bagatell

Institutions: University of Michigan, University of Florida, University of California San Diego, Children's Oncology Group, Boston Children's Hospital, Dana-Farber Cancer Institute, Dana-Farber/Boston Children's Cancer and Blood Disorders Center, St. Jude Children's Research Hospital, Seattle Children's Hospital, Children's Hospital of Philadelphia, University of Wisconsin–Madison, Columbia University Irving Medical Center, Nemours Children's Clinic, University of Washington

Language: English

Topic: Neuroblastoma Research and Treatments

Subfield: Neurology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2890612099

Cites:

Cited by: 4

Related to: 10